NCT01964547 - A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Multiple SclerosisSpasticity

Interventions

DRUG

Sativex

Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).

DRUG

Placebo

Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).

Trial Locations (1)

128 08

MS Centre, Charles University, Prague